Yao Chao, Xue Xin, Jia Yunxi, Li Min, Zhang Lu, Yuan Hong, Xue Huiting, Hu Ruiping
College of Basic Medicine, Inner Mongolia Medical University, Hohhot, China.
Front Cell Infect Microbiol. 2025 Jun 30;15:1593581. doi: 10.3389/fcimb.2025.1593581. eCollection 2025.
INTRODUCTION: Insulin resistance (IR) underlies metabolic diseases such as obesity and diabetes. Statins are lipid-lowering drugs that have also been studied to improve insulin resistance, but the mechanism is not well understood. Metagenomics and metabolomics were used to analyze the main species and metabolic pathways involved in intestinal microbes while improving insulin resistance in mice with rosuvastatin in this study. METHODS: C57BL/6J male mice fed a high-fat diet were used to establish the insulin resistance (IR) mouse model. Rosuvastatin (RSV) was then administered for 8 weeks. Metagenomics and metabolomics were utilized to analyze the microbial composition and short chain fatty acid metabolites in intestinal feces of mice. RESULTS: It was observed that insulin-resistant mice showed significant improvement in insulin resistance following treatment with RSV. In comparison to the HFD group, specific bacterial strains were significantly increased, and the levels of butyric acid, caproic acid, and isovaleric acid among the short-chain fatty acids were notably elevated in the RSV group. Through KEGG enrichment analysis, 19 dominant strains and 15 key enzymes involved in butyric acid metabolism were identified. CONCLUSIONS: The results suggested that IR mice might enhance insulin sensitivity by promoting butyric acid synthesis via intestinal microbes following RSV treatment.
引言:胰岛素抵抗(IR)是肥胖和糖尿病等代谢性疾病的基础。他汀类药物是降脂药物,也被研究用于改善胰岛素抵抗,但其机制尚不清楚。本研究利用宏基因组学和代谢组学分析肠道微生物中参与改善瑞舒伐他汀处理小鼠胰岛素抵抗的主要菌种和代谢途径。 方法:使用喂食高脂饮食的C57BL/6J雄性小鼠建立胰岛素抵抗(IR)小鼠模型。然后给予瑞舒伐他汀(RSV)8周。利用宏基因组学和代谢组学分析小鼠肠道粪便中的微生物组成和短链脂肪酸代谢产物。 结果:观察到胰岛素抵抗小鼠经RSV治疗后胰岛素抵抗有显著改善。与高脂饮食组相比,RSV组特定细菌菌株显著增加,短链脂肪酸中丁酸、己酸和异戊酸水平显著升高。通过KEGG富集分析,鉴定出19种优势菌株和15种参与丁酸代谢的关键酶。 结论:结果表明,IR小鼠在RSV治疗后可能通过肠道微生物促进丁酸合成来增强胰岛素敏感性。
Front Cell Infect Microbiol. 2025-6-30
Eur J Pharmacol. 2025-9-5
Front Endocrinol (Lausanne). 2025-6-6
Nat Rev Microbiol. 2025-5-13
Cell Commun Signal. 2023-8-18
Curr Gastroenterol Rep. 2023-2
J Agric Food Chem. 2022-5-25
Diabetes Metab J. 2022-1